126 related articles for article (PubMed ID: 11365894)
1. Immune reconstitution: conference reports.
Whitfield L
Posit Aware; 1998; 9(5):36-9, 41-3. PubMed ID: 11365894
[TBL] [Abstract][Full Text] [Related]
2. Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient.
Tachikawa N; Yasuoka A; Oka S
Jpn J Infect Dis; 1999 Dec; 52(6):245-6. PubMed ID: 10738363
[No Abstract] [Full Text] [Related]
3. Hydroxyurea in HIV therapy.
HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea for HIV infection.
Zachary KC; Davis B
AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral news.
Gallant JE
Hopkins HIV Rep; 1998 Sep; 10(5):1, 4-7, 11. PubMed ID: 11365773
[TBL] [Abstract][Full Text] [Related]
6. New drugs garner interest; but inhibitors lose shine.
AIDS Alert; 1998 Sep; 13(9):99-100. PubMed ID: 11365795
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
8. Rescue me.
Simmons P
Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea - new observations.
Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
[TBL] [Abstract][Full Text] [Related]
10. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
11. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
[TBL] [Abstract][Full Text] [Related]
12. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
Lisziewicz J; Jessen H; Finzi D; Siliciano RF; Lori F
Lancet; 1998 Jul; 352(9123):199-200. PubMed ID: 9683211
[No Abstract] [Full Text] [Related]
14. Some competition for 1592.
GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
[TBL] [Abstract][Full Text] [Related]
15. Notes on the International AIDS Conference.
Levin J
Posit Aware; 1998; 9(5):33-5. PubMed ID: 11365893
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral rounds. When success is a pain.
Bartlett JG; del Rio C
AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
[No Abstract] [Full Text] [Related]
17. ACTG 343: three drugs better than two for maintaining HIV suppression.
Bowersox J
NIAID AIDS Agenda; 1998 Mar; ():1-2, 10-1. PubMed ID: 11365088
[TBL] [Abstract][Full Text] [Related]
18. ACTG 343: (why) we can't relax our grip on viral suppression.
Maenza JR
Hopkins HIV Rep; 1998 May; 10(3):10. PubMed ID: 11365491
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
Lori F; Jessen H; Lieberman J; Finzi D; Rosenberg E; Tinelli C; Walker B; Siliciano RF; Lisziewicz J
J Infect Dis; 1999 Dec; 180(6):1827-32. PubMed ID: 10558937
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
